1
Completed Has Results Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer- Related Lymphedema Head and Neck Neoplasms Head and Neck LymphedemaHead and Neck Cancer Device: Head and neck garments for pneumatic compression device Drug: NIRFLI with ICG UT Health Science Center at Houston
Completed Has Results Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients WithHead and Neck Cancer Head and Neck Neoplasms Mucositis Drug: Brilacidin Other: Placebo Gilbert, Arizona, United States Lakeland, Florida, United States Columbus, Georgia, United States (and 13 more...)
Terminated Has Results Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer Drug: erlotinib hydrochloride Drug: pemetrexed disodium Procedure: quality-of-life assessment Radiation: intensity-modulated radiation therapy UNC Linberger Comprehensive Cancer Center Wake Forest University Comprehensive Cancer Center
Terminated Has Results Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer ) of theHead and Neck (SCCHN ) Drug: Patritumab Drug: Cetuximab Drug: Cisplatin (and 2 more...) Institut Jules Bordet Univeristair Ziekenhuis Antwerpen UZ Leuven (and 31 more...)
Active, not recruiting Has Results Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Head and Neck Squamous Cell Cancer Biological: pembrolizumab Drug: methotrexate Drug: docetaxel Biological: cetuximab
Completed Has Results Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Carcinoma Biological: Cetuximab Other: Laboratory Biomarker Analysis Drug: Tivantinib Mayo Clinic in Arizona City of Hope Comprehensive Cancer Center USC / Norris Comprehensive Cancer Center (and 21 more...)
Completed Has Results Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients Head and Neck Cancer Acute Pain Postoperative Pain Drug: Gabapentin Drug: Placebo Washington University School of Medicine
Completed Has Results Use of the Passy Muir Swallowing Self Trainer Stroke Brain Injury Head and Neck Cancer Device: Dysphagia retraining with device James Madison University
Terminated Has Results BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer FGFR Gene Amplification FGFR1 Gene Amplification FGFR2 Gene Amplification (and 7 more...) University of Chicago Comprehensive Cancer Center
Terminated Has Results Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma (and 25 more...) Radiation: Stereotactic Body Radiation Therapy Device: Positron Emission Tomography Device: Computed Tomography Other: Quality-of-Life Assessment University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Completed Has Results Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer Recurrent or Metastatic Head and Neck Carcinoma Drug: Vinflunine Drug: Methotrexate Institut de Recherche Pierre Fabre
Active, not recruiting Has Results Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer Carcinoma, Squamous Cell of Head and Neck Drug: Cetuximab Drug: Cisplatin/Carboplatin Drug: 5-fluorouracil Please contact the Merck KGaA Communication Center
Terminated Has Results Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Head and Neck Squamous Cell CarcinomaDrug: Buparlisib Drug: Buparlisib matching Placebo Drug: Paclitaxel Highlands Oncology Group Dana Farber Cancer Institute IRB Washington U School of Medicine Center for Clinical Studies SC - BKM120H2201 (and 55 more...)
Completed Has Results A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin Drug: Valproic Acid Drug: Liothyronine Sodium National Institutes of Health Clinical Center, 9000 Rockville Pike
Completed Has Results Pioglitazone in Thyroid Cancers Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene University of Colorado University of Michigan University of Pennsylvania University of Texas MD Anderson Cancer Center
Completed Has Results Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer Drug: Temsirolimus and Sorafenib Memorial Sloan-Kettering at Basking Ridge Memorial Sloan-Kettering Cancer Center @ Suffolk Memorial Sloan Kettering Cancer Center (and 2 more...)
Completed Has Results Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Differentiated Thyroid Cancer Drug: Selumetinib Drug: Placebo Drug: Radioactive Iodine Therapy Research Site Research Site Research Site (and 42 more...)
Completed Has Results Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Recurrent Salivary Gland Cancer Stage IVA Salivary Gland Cancer Stage IVB Salivary Gland Cancer Stage IVC Salivary Gland Cancer Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Terminated Has Results CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Thyroid Neoplasms Poorly Differentiated and Undifferentiated Thyroid Cancer Differentiated Thyroid Cancer National Institutes of Health Clinical Center
Completed Has Results Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer Esophageal Cancer Gastroesophageal Junction Cancer Drug: Sorafenib, administered orally Procedure: CT/MRI Memorial Sloan Kettering Cancer Center
Completed Has Results BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer Esophageal Cancer Gastric Cancer Drug: Cetuximab,Paclitaxel, Carboplatin Brown University Oncology Group
Terminated Has Results Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Advanced Cancer Breast Cancer Gastric Cancer (and 2 more...) Drug: Pembrolizumab Drug: Trastuzumab Drug: ado-trastuzumab emtansine Drug: Cetuximab Western Regional Medical Center/Cancer Treatment Center of America
Active, not recruiting Has Results Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Liver Cancer Anxiety Disorder Depression (and 7 more...) Other: Early palliative care UC San Diego Moores Cancer Center Queen's Medical Center University of Chicago Comprehensive Cancer Center (and 20 more...)
Terminated Has Results A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Medullary Thyroid Carcinoma Drug: Bortezomib Drug: Vandetanib National Institutes of Health Clinical Center, 9000 Rockville Pike
Completed Has Results Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Adenocarcinoma of the Gastroesophageal Junction Esophageal Undifferentiated Carcinoma Gastric Adenocarcinoma (and 14 more...) Other: Laboratory Biomarker Analysis Drug: Oxaliplatin Drug: Pralatrexate Roswell Park Cancer Institute Rochester General Hospital
Active, not recruiting Has Results A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Biological: pembroliziumab Drug: paclitaxel
Completed Has Results Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy Thyroid Neoplasms Goiter, Nodular Thyroid Nodule (and 2 more...) Procedure: Superficial Cervical Plexus Block Procedure: Local Wound Infiltration Drug: 0.9% saline Drug: Marcaine University of Chicago Medical Center
Active, not recruiting Has Results Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer Hereditary Thyroid Gland Medullary Carcinoma Multiple Endocrine Neoplasia Type 2A Multiple Endocrine Neoplasia Type 2B (and 6 more...) Other: Laboratory Biomarker Analysis Other: Pharmacological Study Drug: Sorafenib Tosylate Washington University School of Medicine Duke University Medical Center Ohio State University Comprehensive Cancer Center
Completed Has Results A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer Lung Cancer Esophageal Cancer University of Virginia
Active, not recruiting Has Results Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Gastric Cancer Third Line Drug: Avelumab Drug: Irinotecan Drug: Paclitaxel Other: Best Supportive Care (BSC) Rocky Mountain Cancer Centers 1800 Williams Street, Suite 100 Rocky Mountain Cancer Centers, LLP 3676 Parker Blvd #350 Advanced Medical Specialties 8940 North Kendall Drive, Suite 300E (and 72 more...)
Terminated Has Results Metabolomic and BH3 Profiling of EsophagealCancers : Identification of Novel Assessment Methods of Treatment Response for Precision Therapy Esophageal Cancer Esophageal Adenocarcinoma Esophageal Squamous Cell Cancer (and 2 more...) Other: Chemoradiotherapy Procedure: Esophagectomy National Institutes of Health Clinical Center
Completed Has Results Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Ovary Cancer Cervix Cancer Endometrium Cancer (and 4 more...) Drug: Tisotumab vedotin (HuMax-TF-ADC) MD Anderson Cancer Center Institut Jules Bordet Universitaire Ziekenhuizen Leuven (and 13 more...)
Completed Has Results A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Drug: Ramucirumab Drug: Paclitaxel City of Hope National Medical Center University of Kansas Medical Center Dana Farber Cancer Institute (and 49 more...)
Terminated Has Results Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma Biological: CRS-207 Biological: Pembrolizumab UCLA Medical Center University of Colorado University of Chicago Medical Center (and 5 more...)
Completed Has Results Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Cervical Cancer Oropharyngeal Cancer Vaginal Cancer (and 2 more...) Drug: Fludarabine Drug: Cyclophosphamide Biological: Young TIL Drug: Aldesleukin National Institutes of Health Clinical Center, 9000 Rockville Pike
Active, not recruiting Has Results A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Metastatic Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Drug: Ramucirumab Drug: Placebo Drug: S-1 (and 2 more...) For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. (and 31 more...)
Completed Has Results The Passy Muir Swallowing Self Training Device Device: Vibrotactile stimulation James Madison University and Rockingham Memorial Hospital
Completed Has Results Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma Winship Cancer Institute of Emory University University of Chicago Dana Farber Cancer Institute (and 22 more...)
Completed Has Results NBI to Detect Post-RT Mucosal Residual NPC Device: Laryngoscope with NBI system Pamela Youde Nethersole Eastern Hospital 
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου